|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
NOVEMBER 21, 2005
Salix Pharmaceuticals: What The Gut Tells You  Salix Pharmaceuticals (SLXP
) is the small fry in gastrointestinal drugs, with Johnson & Johnson (JNJ
) and GlaxoSmithKline (GSK
) the biggies. But Salix is a pure play in that growing market, says Peggy Farley of Ascent Capital Management, which owns shares. Its chief product, Colazal, treats colitis -- inflammation of the colon. Its other drug, Xifaxan, is for travelers' diarrhea. On Oct. 3, Salix completed a purchase of InKine Pharmaceutical, whose products diagnose and treat stomach ills. InKine's new drug is a tablet used prior to colonoscopy. Farley says InKine should add at least $60 million to Salix' revenues and 2 cents a share to earnings. On Nov. 8, Salix posted third-quarter results that beat analysts' forecasts, driving the stock up from 17.40 to 19.44 that day. Farley sees the stock at 24 by the end of 2005 and 36 in 12 months. Deborah Knobelman of Piper Jaffray (PJC
) just raised her 2005 earnings estimate from 61 cents to 69 cents a share on sales of $151 million, including InKine's sales. In 2004 it earned 18 cents on sales of $105 million.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  BY GENE G. MARCIALBy Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2005, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version